
Opinion|Videos|November 9, 2023
KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer
Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5











































